Brought to you by 
Ablynx NV IPO on Euronext raises €75mm
03 Aug 2020
Executive Summary
Therapeutic antibody company Ablynx NV has completed a €75mm ($108.6mm) IPO on the Euronext Brussels Exchange. The company sold 10.7mm shares at €7 apiece, within its estimated €6.50-8.50 range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ablynx NV IPO on Euronext raises €75mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice